NCT03800472已完成1 期
A Phase I, Randomized, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Including the Effect of Food, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG3312, in Adult, Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- Frequency and severity of treatment emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations
研究概览
简要总结
The purpose of this study is to investigate how safe 2 different formulations (immediate-release (IR) and modified-release (MR) tablets) of the new compound GLPG3312 are and how well they are tolerated when they are administered to healthy volunteers. Immediate-release and modified-release tablets contain the same active ingredient, but the modified-release tablet is covered with a protective layer, so it will dissolve in the intestines and not in the stomach. GLPG3312 has not been administered to humans before. Next to assessing the safety and tolerability, the purpose of this study is to investigate how food affects how quickly and to what extent GLPG3312 in a modified release formulation is absorbed and eliminated from the body. In addition, the effect of GLPG3312 on the body will be investigated by evaluating the effect of GLPG3312 on markers of the immune response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female between 18 to 55 years of age (extremes included), on the date of signing the Informed Consent Form (ICF). Female should be of non-childbearing potential defined as permanently surgically sterile (bilateral oophorectomy, i.e. surgical removal of ovaries, bilateral salpingectomy or hysterectomy, i.e. surgical removal of uterus), or with no menses for 12 or more months without an alternative medical cause AND a folliclestimulating hormone (FSH) level >35 IU/L. These subjects must also have a negative pregnancy test. For surgical sterilization, documented confirmation will be requested.
- •A body mass index (BMI) between 18 to 30 kg/m2, inclusive.
- •Subject must be able and willing to comply with restrictions on prior medication.
- •Male subjects with female partners of childbearing potential must be willing to comply with contraceptive methods.
- •Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and fasting clinical laboratory safety tests. Clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered nonclinically significant in the opinion of the investigator. At minimum hemoglobin, alanine aminotransferase (ALT), creatinine, creatine kinase-myoglobin (CK-MB), High Sensitivity Troponin I, Troponin T and alkaline phosphatase must be within the normal range, aspartate aminotransferase (AST) must be no greater than 1.5x upper limit of normal range (ULN).
排除标准
- •Known hypersensitivity to IMP ingredients or history of a significant allergic reaction to IMP ingredients as determined by the investigator.
- •Positive serology for HBsAg, or hepatitis C virus (HCV), or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of the IMP.
- •History of, or a current immunosuppressive condition (e.g. HIV infection).
- •Having any illness (e.g. active allergy, fever, hypersensitivity reactions) judged by the investigator as clinically significant, in the 3 months prior to first dosing of the IMP.
- •Any history, or current sign or symptom of a cardiovascular, renal, or metabolic bone disease or disease of bone remodelling (with the exception of uncomplicated accidental bone fractures that recovered uncompromised at least 1 year ago), or any history of endocrine disease, including an abnormal laboratory result for prespecified clinical laboratory safety parameters related to these conditions.
- •Presence or sequelae of gastrointestinal, liver, kidney (creatinine clearance ≤80 mL/min/1.73m2, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula: if calculated result is ≤80 mL/min/1.73m2, a 24-hours urine collection can be done), or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •History of malignancy within the past 5 years prior to screening with the exception of excised and curatively treated non-metastatic cell carcinoma of the skin or carcinoma in situ of the cervix which is considered cured with minimal risk of recurrence.
- •Significant blood loss (including blood donation >450 mL), or transfusion of any blood product within 12 weeks prior to screening.
- •Treatment with any medication (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and a maximum of 10 g/ 2 weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer, prior to the first dosing of the IMP.
- •Active drug abuse or alcohol abuse (alcohol abuse defined as regular weekly intake of more than 14 units) within 2 years prior to first IMP administration.
- •Active smoker and/or has used nicotine or nicotine-containing products within the past 6 months before the first IMP administration.
- •Regular consumption of a large quantity of caffeinated coffee, tea (> 6 cups per day) or equivalent.
- •Concurrent participation or participation in a drug, drug/device or biologic investigational research study within 12 weeks or 5 half-lives of the IMP, whichever is longer, prior to first dosing of the investigational medicinal product (IMP).
- •Any clinical laboratory test result outside of the reference ranges considered by the investigator as clinically significant. Hemoglobin, ALT, creatinine, CK-MB, High Sensitivity Troponin I, Troponin T, or alkaline phosphatase outside normal range, AST result greater than 1.5x ULN.
- •History or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g. known long QT syndrome). A first-degree atrioventricular block will not be considered as a significant abnormality. QTcF = QT x (1000/RR)1/3 (QTcF) >450 ms (male), >460 ms (female) (mean values per parameter will be considered) detected on the 12-lead ECG.
研究组 & 干预措施
Placebo MAD MR (Part 4)
Placebo Comparator
Multiple doses of Placebo MR
干预措施: Placebo (Drug)
Placebo SAD IR (Part 1)
Placebo Comparator
Single doses of Placebo IR
干预措施: Placebo (Drug)
GLPG3312 SAD IR (Part 1)
Experimental
Single doses of GLPG3312 IR
干预措施: GLPG3312 IR (Drug)
GLPG3312 SAD MR (Part 2)
Experimental
Single doses of GLPG3312 MR
干预措施: GLPG3312 MR (Drug)
Placebo SAD MR (Part 2)
Placebo Comparator
Single doses of Placebo MR
干预措施: Placebo (Drug)
GLPG3312 FE MR (Part 3)
Experimental
Single dose of GLPG3312 MR in fed and fasted state
干预措施: GLPG3312 FE MR (Drug)
GLPG3312 MAD MR (Part 4)
Experimental
Multiple doses of GLPG3312 MR
干预措施: GLPG3312 MR (Drug)
GLPG3312 MAD MR optimized (Part 4)
Experimental
Multiple doses of GLPG3312 MR
干预措施: GLPG3312 MR (Drug)
Placebo MAD MR optimized (Part 4)
Placebo Comparator
Multiple doses of Placebo MR
干预措施: Placebo (Drug)
结局指标
主要结局
Frequency and severity of treatment emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations
时间窗: From screening through study completion, an average of 9 months.
To evaluate the safety and tolerability of oral single and multiple ascending doses of GLPG3312, in adult, healthy, subjects, when given as Immediate Release (IR) formulation (in fasted conditions) or as Modified Release (MR) formulation (in fasted and fed conditions)
次要结局
- Maximum observed plasma concentration (Cmax) of GLPG3312 (μg/mL) (Part 2)(Between Day 1 pre-dose and Day 7)
- Area under curve (AUC) of GLPG3312 (μg.h/mL) (Part 4)(Between Day 1 pre-dose and Day 21)
- Cumulative amount of GLPG3312 excreted in feces (Aefeces)(mg) (Part 4)(Between Day 1 pre-dose and Day 21)
- Ratio in extent and exposure following dosing of GLPG3312 as MR tablets under fed conditions (high-fat high calorie) versus fasted conditions (Part 3)(Between Day 1 pre-dose and Day 7)
- Maximum observed plasma concentration (Cmax) of GLPG3312 (μg/mL) (Part 4)(Between Day 1 pre-dose and Day 21)
- Area under curve (AUC) of GLPG3312 (μg.h/mL) (Part 2)(Between Day 1 pre-dose and Day 7)
- Maximum observed plasma concentration (Cmax) of GLPG3312 (μg/mL) (Part 1)(Between Day 1 pre-dose and Day 4)
- Area under curve (AUC) of GLPG3312 (μg.h/mL) under fed conditions (high-fat high calorie) versus fasted conditions (Part 3)(Between Day 1 pre-dose and Day 7)
- Terminal elimination half-life (t1/2) of GLPG3312 (h) (Part 1)(Between Day 1 pre-dose and Day 4)
- Cumulative amount of GLPG3312 excreted in urine (Aeurine)(mg) (Part 2)(Between Day 1 pre-dose and Day 7)
- Cumulative amount of GLPG3312 excreted in urine (Aeurine)(mg) (Part 4)(Between Day 1 pre-dose and Day 21)
- Maximum observed plasma concentration (Cmax) of GLPG3312 (μg/mL) under fed conditions (high-fat high calorie) versus fasted conditions (Part 3)(Between Day 1 pre-dose and Day 7)
- Area under curve (AUC) of GLPG3312 (μg.h/mL) (Part 1)(Between Day 1 pre-dose and Day 4)
- Terminal elimination half-life (t1/2) of GLPG3312 (h) (Part 2)(Between Day 1 pre-dose and Day 7)
- Terminal elimination half-life (t1/2) of GLPG3312 (h) (Part 4)(Between Day 1 pre-dose and Day 21)
- Ratio in extent and exposure following dosing of GLPG3312 as MR formulation compared to following dosing as IR formulation, under fasted conditions (Part 1 versus Part 2)(Between Day 1 pre-dose and Day 4)
- Cumulative amount of GLPG3312 excreted in urine (Aeurine)(mg) (Part 1)(Between Day 1 pre-dose and Day 4)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and ChildrenDengue Hemorrhagic FeverDengue Shock SyndromeDengue FeverNCT00468858U.S. Army Medical Research and Development Command636
已完成
2 期
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAGGlaucomaOcular HypertensionNCT00967811Mati Therapeutics Inc.83
已完成
1 期
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT01392976Clovis Oncology, Inc.17
已完成
1 期
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 YearsHerpes SimplexNCT05989672GlaxoSmithKline50
撤回
1 期
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenHIV SeronegativityHIV InfectionsNCT00000809National Institute of Allergy and Infectious Diseases (NIAID)